FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management

Non-small-cell lung cancer (NSCLC) is the most common form of primary lung cancer. The discovery of several oncogenic driver mutations in patients with NSCLC has allowed the development of personalized treatments based on these specific molecular alterations, in particular in the tyrosine kinase (TK...

Descripción completa

Detalles Bibliográficos
Autores principales: Solassol, Isabelle, Pinguet, Frédéric, Quantin, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921037/
https://www.ncbi.nlm.nih.gov/pubmed/31671561
http://dx.doi.org/10.3390/biom9110668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921037/
https://www.ncbi.nlm.nih.gov/pubmed/31671561
http://dx.doi.org/10.3390/biom9110668

Ejemplares similares